focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Good point, Matty. Greetings to PCS1954 and HBD, both of whom raised the matter yesterday of potential shareholder influence on the BoD. If B-B can become our proxy influence, that would be marvellous. Naturally he cannot be given privileged information, but if it were known that he was in contact, his positive comments here would be misinterpreted as that. Good is best done, they say, by stealth.
How do we know, HBD, that our hero and saviour, B-Bunter, does not have - and reasonably - just such access to the BoD? The last thing he could do is to say so, otherwise his positive comments here would be taken as release of privileged information. Let us hope that it is so, but absolutely do not respond, one way or the other, Bill !
I too missed the indication of going straight on to phase 2a. The reason I missed it was that I took it to be a (hope-filled) aspiration, i.e. that 1b could be done over the second half of 2024 and 2a, subject - mind you - to funding etc., begun by year-end. Chairman's statements are the place to bang the drum. But was I wrong?
Dear Billy,
I am interested in your optimism. A small group met at the Red Lion, Hinxton - your excellent suggestion - at the end of last month. Would you be prepared to meet us there at a day/time of your choosing?
Regards,
P.
I suspect it is not a pharma at all but a financial vehicle hoping successfully to commercialise the asset. Where CPF has achieved lukewarm results, they can perhaps with energy and intelligent outsourcing or sublicensing do better. Any views anyone?
So I take it that we none of us know how many other (small, unlisted) companies have a stake in 737. If CPF (using Sixth Element Capital) negotiates as an umbrella for, say, three or four entities who did the work outsourced by CRT, how much incentive do they have to obtain a speedy and meaningful outcome? Could that go some way towards explaining the delay? Others have drawn attention to an apparent lack of engagement on the part of Sixth Element. I ask for information. How do these things work? Potnak, Sad, others, I need your help!
It was pleasing to learn this morning that John found nothing untoward when he trawled through the data and that the company is still optimistic about the prospects for the compound. But still no indication of a positive (or any) kind as to why the matter is taking so long to resolve.
As a side-issue, what other stakeholders are there, do we know (or can we guess)? If we were one small company, doing 27.5% of the work, how many others were there? Do we perhaps hold less than the largest stake among them?
Potnak,
Greetings, one of my most respected posters.
Outright sale of 737 is indeed greatly to be desired. Would it not, however, be odd for CRT + SAR to sell outright to someone else, when CRT has just announced a tie-up with Merck? And if the tie-up is to make sense, would not CRT (if not, as I think, SAR) need to retain significant skin in the new game?
Last Friday Krone and Basser1 drew attention to the collaborative tie-up announced between Merck and CRT.
I find this deeply fascinating in view of Merck's Keytruda being one of the leading compounds considered to be in the frame for potential enhancement by combination with 737.
It would not be surprising if 737 needed further development in order to fit the profile of Keytruda.
SAR has its hands full with progression of 1801 and 1802 at present. Its earlier 27.5% contribution to the work would rapidly diminish.
Would it not make sense for Merck to buy out SAR's current 27.5% share of 737 plus ,say, 22.5% of CRT's as well, so as to advance development on a 50:50 basis with CRT, using doubtless the nine researchers they plan to instal with them?
I hesitate to put a value on 737 in its current condition, but Sad has put it as high as £700m. 27.5% of even half to two thirds of this would solve SAR's funding problems with 1801/1802 (and some).
Over to those better qualified than I am to comment on this. I stress that these speculations are entirely my own and that I may well be totally wrong. But what, I wonder, did Tim mean by his recent information that CPF is now taking the lead in evaluating potential further development opportunities for 737?